A case report of *Talaromyces marneffei* Oro-pharyngo-laryngitis: a rare manifestation of Talaromycosis

Thanyarak Wongkamhla 1, Piriyaporn Chongtrakool 2 and Anupop Jitmuang 1*

**Abstract**

**Background:** The incidence of *Talaromyces marneffei* infection in HIV-infected individuals has been decreasing, whereas its rate is rising among non-HIV immunodeficient persons, particularly patients with anti-interferon-gamma autoantibodies. *T. marneffei* usually causes invasive and disseminated infections, including fungemia. *T. marneffei* oro-pharyngo-laryngitis is an unusual manifestation of talaromycosis.

**Case presentation:** A 52-year-old Thai woman had been diagnosed anti-IFNγ autoantibodies for 4 years. She had a sore throat, odynophagia, and hoarseness for 3 weeks. She also had febrile symptoms and lost 5 kg in weight. Physical examination revealed marked swelling and hyperemia of both sides of the tonsils, the uvula and palatal arches including a swelling of the epiglottis, and arytenoid. The right tonsillar biopsy exhibited a few intracellular oval and elongated yeast-like organisms with some central transverse septum seen, which subsequently grew a few colonies of *T. marneffei* on fungal cultures. The patient received amphotericin B deoxycholate 45 mg/day for 1 week, followed by oral itraconazole 400 mg/day for several months. Her symptoms completely resolved without complication.

**Conclusion:** In patients with anti-IFN-γ autoantibodies, *T. marneffei* can rarely cause a local infection involving oropharynx and larynx. Fungal culture and pathological examination are warranted for diagnosis *T. marneffei* oro-pharyngo-laryngitis. This condition requires a long term antifungal therapy.

**Keywords:** *Talaromyces marneffei*, Talaromycosis, Oro-pharyngo-laryngitis, Anti-interferon-gamma autoantibodies

**Background**

*Talaromyces marneffei* (formerly known as *Penicillium marneffei*) is an important dimorphic fungus; it is the only member in the genus causing systemic mycosis and is more prevalent in Southeast Asia [1–3]. Historically, human *T. marneffei* infection has been confined to patients with acquired immunodeficiency syndrome (AIDS) [1]. In recent years, the incidence of *T. marneffei* infection in those populations has been decreasing following treatment with highly active antiretroviral regimens and preventive measurements. However, the rate of this infection in non-HIV-infected individuals has been rising, particularly in patients with anti-interferon-gamma autoantibodies (anti-IFNγ autoantibodies), patients receiving systemic corticosteroids or immunosuppressive agents, organ transplant recipients, and patients receiving novel anti-cancer targeted therapies [4]. When *T. marneffei* infects those populations, it usually causes fungemia and disseminated disease to various organs, such as the skin, lymph node, lung, spleen, and bone [4, 5].

Oro-pharyngo-laryngitis caused by *T. marneffei* is a very uncommon talaromycosis, and has been rarely reported, with previous case reports of *T. marneffei* oro-pharyngitis and pharyngo-laryngitis limited to patients with underlying AIDS [6–8]. Herein, we report a rare manifestation of talaromycosis in a woman who had underlying anti-IFNγ autoantibodies. She presented with subacute oro-pharyngo-laryngitis, which was rapidly resolved following a systemic antifungal therapy.
A 52-year-old Thai woman had been diagnosed anti-IFNγ autoantibodies for 4 years. Four years ago (March 2015), she presented with prolonged fever, a weight loss of approximately 10 kg, bilateral tonsillar enlargement, and multiple cervical lymphadenopathy. A lymph node biopsy from the left cervical node showed the growth of *Mycobacterium abscessus*. Disseminated *Mycobacterium abscessus* infection was diagnosed. She denied using illicit drugs, herbal medicines, or corticosteroids. Immunological studies, including anti-HIV testing, were all negative, but anti-IFNγ autoantibodies tested highly positive. She received intravenous imipenem and amikacin for a primary anti-mycobacterial therapy, which were later switched to oral clarithromycin and ciprofloxacin for maintenance therapy. She had relapse infections twice during the course of treatment. Thereafter, the anti-mycobacterial regimen was changed to oral clarithromycin and linezolid. Following the new regimen, she complied well with the treatment, and her condition was in remission for 1 year. Before this admission, she had a sore throat, which was particularly more painful at the right side of the pharynx, odynophagia, and hoarseness for 3 weeks. She also had febrile symptoms and lost 5 kg in weight. She received oral amoxicillin 1.5 g/day from a primary physician, but her symptoms did not resolve. She denied foreign body sensation, and had no dysphagia, stridor, or difficult breathing. Physical examination revealed marked swelling and hyperemia of both sides of the tonsils, including the uvula and palatal arches (Fig. 1), and a single left submandibular lymph node, sized approximately 1 cm, was identified. Indirect laryngoscopy demonstrated a moderate swelling of the epiglottis, arytenoid, and vocal cord with normal airway opening. There were no skin papules or nodules, including no hepatosplenomegaly found. Blood chemistries, including plain chest radiography, were unremarkable. The patient was performed right tonsillar biopsy at 1 day following admission. The tissue biopsy Gram stain (Fig. 2a), including the pathological sections, exhibited a few intracellular oval and elongated yeast-like organisms with some central transverse septum seen with dense small lymphoid cell and plasma cell infiltrates. Acid fast and modified acid fast staining from the pathological sections were negative. One week later, the tissue biopsy grew few mold colonies with the typical diffusible red-colored pigment on the fungal cultures (Fig. 2b). Morphological identification based on lactophenol cotton blue microscopic examination demonstrated these to be hyaline septate molds, with branched and non-branched conidiophores consisting of brush-like phialides with long chains of round and elliptical conidia (Fig. 2c). All of the findings were suggestive of *T. marneffei*. However, antifungal susceptibility testing was not performed due to there being no standard breakpoint criteria for interpretation. The tissue sent for bacterial and mycobacterial culture showed no significant growth. Routine blood cultures (BD BACTEC™, Becton, Dickinson and Company), including fungal and mycobacterial blood cultures (BD BACTEC™ Myco/F Lytic, Becton, Dickinson and Company) were negative for any microorganisms. Thus, no evidence of relapsed mycobacterial disease or other pathogen co-infections was detected.

Following the diagnosis of *T. marneffei* infection, amphotericin B deoxycholate 45 mg/day (0.6 mg/kg/day) was commenced as the primary antifungal therapy. The patient continued receiving oral clarithromycin and linezolid for *M. abscessus* maintenance therapy. Following 5 days of amphotericin therapy, the patient developed acute kidney injury with a rising creatinine level from 0.86 to 2.44 mg/dL. Her blood potassium, magnesium, and bicarbonate levels were 3.4, 1.7, and 24 mEq/L, respectively. Finally, the antifungal regimen was changed to itraconazole oral solution with a daily dose of 400 mg/day after receiving amphotericin B for 5 days. The presenting symptoms of a sore throat and odynophagia disappeared after 1 week of the antifungal therapy. Four weeks after the treatment, the swelling of the pharynx and larynx were markedly reduced. She was continued with itraconazole for 4 months, and later a dose of 200 mg/day was used for long-term secondary prophylaxis. Her symptoms completely resolved with no complication. She still has been receiving the itraconazole prophylaxis until now.

**Discussion**

*T. marneffei* infection is an opportunistic fungal infection that is increasingly reported among non-HIV
infected adults and children [9–13]. A previous cohort study from Thailand reported that 22 from 34 non-HIV infected cases with T. marneffei infections had no previously known underlying diseases and no apparent immunodeficiencies [11]. Of those 22 cases, blood samples from 9 cases were tested for immunological studies, and all were positive for anti-IFN\(\gamma\) autoantibodies by ELISA. According to the study, the anti-IFN\(\gamma\) autoantibody may be a newly associated risk factor for T. marneffei infection in non-HIV infected individuals [11]. Anti-IFN\(\gamma\) autoantibody is an acquired adult onset immunodeficient condition and its pathophysiology has not yet been clearly described. We still do not know how the autoantibodies are acquired, where from, and why this immunodeficient condition is usually found in adulthood, particularly in Asian populations. Some specific HLA classes, such as HLA-DRB1, and HLA-DQB1 commonly discovered in Asian populations were proposed to be associated with this condition [14, 15]. Clinical infections of patients with anti-IFN\(\gamma\) autoantibodies are usually disseminated diseases caused by opportunistic pathogens, such as non-tuberculous mycobacteria, particularly rapidly growing mycobacteria, Salmonella non-Typhi, Cryptococcus, Histoplasma, Talaromyces, and the Varicella-Zoster virus [16, 17]. Similar to this case report, more than half of patients developed relapsed infection from a prior infected organism or recurrent infection from a new opportunistic organism despite receiving long-term antimicrobial treatment [17].

T. marneffei infection in both HIV-infected and non-HIV-infected individuals usually manifests as fungemia and disseminated disease to various organs [11, 13, 18]. This case report presented with a subacute onset of oro-pharyngo-laryngitis caused by T. marneffei. T. marneffei oro-pharyngo-laryngitis is a rare and atypical presentation of talaromycosis. Previous case reports, including the present case, are summarized in Table 1 [6–8, 19–21]. Most of the case reports, including the present case, had underlying immunodeficiencies as predisposing factors. In HIV-infected patients with low CD\(_4\) T cell counts, T. marneffei oro-pharyngo-laryngitis may present as a part of disseminated talaromycosis. Several case reports demonstrated that oro-pharyngo-laryngitis coincided with systemic involvements, such as multiple skin lesions, lymphadenopathy, and hepatosplenomegaly [6, 9, 21]. This infection presented as subacute or chronic painful papular or ulcerative lesions localized to the oropharyngeal area or progressed to involve the laryngeal area, and sometimes it would not be recognized by the clinician. Presenting symptoms vary based on the area of mucosal involvement, such as painful...
Table 1 A summary of case reports of Talaromyces marneffei oro-pharyngo-laryngitis

| Country, no. of case (Year) | Age (yrs.)/ Sex | Predisposing conditions | Duration of symptoms | Clinical manifestations | Diagnosis | Treatments | Outcomes |
|----------------------------|-----------------|-------------------------|---------------------|------------------------|-----------|------------|----------|
| Thailand, 2 (1997) [19]    | 29/ F, na/ F    | HIV infection           | na                  | Painful oral papules and skin papules (1); Oral ulcers (1) | Tissue culture, histopathology | na         | na       |
| Thailand, 1 (2000) [8]     | 25/ F           | HIV infection           | 3 months            | Sore throat, multiple oral papules | Microscopic exam, tissue culture | Oral KET, ART | Cure     |
| Hong Kong, 1 (2001) [7]    | 63/ M           | HIV infection           | 2 months            | Painful multiple oral ulcerations | Tissue, urine and blood cultures, histopathology | IV AMB, then oral ITRA, ART | Cure     |
| China, 1 (2012) [20]       | 39/ M           | None                    | 4 months            | Chronic painful granuloma like oral ulceration | Histopathology, molecular assay, electron microscopy | Oral ITRA | Cure     |
| India, 1 (2017) [21]       | 33/ M           | HIV infection           | 2 months            | Fever, hoarseness, odynophagia, multiple skin papules | Tissue culture, histopathology | IV AMB, then oral ITRA, ART | Cure     |
| China, 7 (2017) [6]        | Median 34/ M (7)| HIV infection           | na                  | Fever (7), sore throat (7), regional lymphadenopathy (7), mucosal ulceration (6), skin lesions (5), hepatosplenomegaly (5), hoarseness (4), local mass (4) | Tissue culture, blood culture, histopathology | IV AMB, then oral antifungals (FLU, ITRA) (5), ART (7) | Dead (3), improved (4) |
| The present case           | 52/F            | Anti-IFNγ autoantibodies| 3 weeks             | Fever, sore throat, hoarseness, odynophagia | Microscopic exam, tissue culture, histopathology | IV AMB, then oral ITRA | Cure     |

ABD amphotericin B deoxycholate, Anti-IFNγ autoantibodies anti-interferon-gamma autoantibodies, ART antiretroviral therapy, F female, FLU fluconazole, HIV human immunodeficiency virus, ITRA itraconazole, IV intravenous, KET ketoconazole, M male, na not available, yrs. years

oropharyngeal lesions, odynophagia, and hoarseness. However, painful oropharyngeal lesions in HIV-infected individuals have several etiologies, such as aphthous ulceration, herpes simplex infection, erythema multiforme, lymphoma, and histoplasmosis [19, 22]. Thus, the diagnosis of T. marneffei oro-pharyngo-laryngitis requires tissue microscopic examination and a histopathological finding of spherical, oval, and elongated yeast cells with clear central transverse septations, according to the case reports in Table 1. However, the morphological identification of T. marneffei from a tissue section is not specific because its morphology is occasionally identical to Histoplasma capsulatum and some Candida spp., so tissue fungal culture and isolation are warranted for confirmed diagnosis. The present case was undergoing tonsillar biopsy for microbiological diagnosis very early because recurrent mycobacterial infection and invasive mycoses were highly suspected. In this case, microscopic examination with tonsillar biopsy Gram stain could provide a presumptive diagnosis of talaromycosis (Fig. 2a), and later the tissue fungal culture showed characteristic colonies of T. marneffei (Fig. 2b). A previous study demonstrated an early microscopic examination of the sample could give a presumptive diagnosis before the fungal isolation in approximately 60% of cases [23]. In cases of disseminated infection listed in Table 1, T. marneffei were also isolated from blood and urine cultures [6, 7]. The present case was probably not the disseminated infection because the clinical findings showed no evidence of distant organ involvement, including blood culture negative for the fungal isolate. However, the route of T. marneffei oro-pharyngo-laryngitis remains unclear, though inhalation or ingestion of contaminated fungal spores may likely be the route of infection. The oropharynx and tonsil are the primary sites for fungal inoculation following inhalation and ingestion. Partial immunity and more inflammatory response to the fungal organism could explain the shorter onset of the patient’s symptoms compared to several reported cases.

A treatment regimen of talaromycosis prefers initial induction with a systemic antifungal agent, particularly intravenous amphotericin B for a few weeks, followed by maintenance oral antifungal therapy, particularly itraconazole, and subsequently a continuation of secondary prophylaxis for several weeks [24]. The treatment regimen is generally applied for HIV-infected or immunodeficient persons who have frequently presented with disseminated infection. For T. marneffei oro-pharyngo-laryngitis, the treatment regimen has not yet been clearly defined, but it should be based on severity and host immune status. An oral antifungal therapy alone would be appropriate for a localized infection similar to the previous reports [8, 18], whereas an initial intravenous antifungal therapy should be used for severe or extensive T. marneffei infection and for an infection occurring in immunodeficient persons. Most of the previous cases, including the present case, did respond well to the antifungal therapy, although 2 cases died from delayed...
antifungal therapy and 1 died from unresponsive treat-
ment. Treatment outcomes are also based on host im-
munity. In HIV-infected persons, antiretroviral treatment
should be started early to raise the CD4 T cell counts
when diagnosing T. marneffei infection [6, 18, 24]. Sec-
ondary antifungal prophylaxis can be discontinued when
the numbers from the CD4 T cell counts are increasing
sufficiently regarding the recommendation [24]. However,
in patients with anti-IFNγ autoantibodies, a standard anti-
fungal treatment regimen, including long-term antifungal
therapy, has still not been established. The author consid-
ered a continuation of long-term antifungal prophylaxis
to prevent relapse of the T. marneffei infection in this case.
In conclusion, in patients with anti-IFN-gamma autoanti-
bodies, T. marneffei can rarely cause a local infection in-
volving the pharynx and larynx. Fungal culture,
microscopic examination, and histopathological study are
warranted for the diagnosis of T. marneffei oro-pharyngo-
laryngitis. A long-term antifungal therapy was required to
successfully treat this infection.

Abbreviations
AID: amphotericin B deoxycholate; Anti-IFNg autoantibodies: anti-interferon-
gamma autoantibodies; ART: antiretroviral therapy; F: female;
FLU: fluconazole; HIV: human immunodeficiency virus; ITRA: itraconazole;
IV: intravenous; KET: ketoconazole; M: male; na: not available; yrs.: years

Acknowledgements
The authors would like to acknowledge the staff of Mycology Laboratory
Unit, Department of Microbiology for providing the microbiological data.

Authors’ contributions
TW and AJ carried out the clinical follow up and drafted the manuscript. PC
supervised mycology laboratory, antifungal susceptibility testing, fungal
identification, and molecular typing. All authors read and approved the manuscript.

Funding
Not applicable.

Availability of data and materials
All data and materials of this article are included in the manuscript and thus
available to the reader.

Ethics approval and consent to participate
This case report has been granted an exemption from requiring ethics
approval according to the Scientific Ethics Committee of the Siriraj
Institutional Review Board (SIRB), Faculty of Medicine Siriraj Hospital, Mahidol
University.

Consent for publication
Written informed consent was obtained from the participating patient for
publication of this case report and any accompanying images. A copy of the
written consent is available for review upon request.

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of Infectious Diseases and Tropical Medicine, Department of
Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang
Road, Bangkoknoi, Bangkok 10700, Thailand. 2Department of Microbiology,
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
transmission electron microscopic observation from formalin-fixed paraffin-embedded tissues. Med Mycol Case Rep. 2012;2:15–8.

21. Lalunhluah C, Devi SB, Chanu KJ, Singh KB. Hoarseness due to penicillium marneffei infection- an unusual presentation. Int J Med Dent Sci. 2017;6(1):1426–9.

22. Batavia AS, Secours R, Espinosa P, Jean Juste MA, Severe P, Pape JW, et al. Diagnosis of HIV-associated oral lesions in relation to early versus delayed antiretroviral therapy: results from the CPRA HT001 trial. PLoS One. 2016;11(3):e0150666.

23. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet. 1994;344:110–3.

24. Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE, National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(9):1308–11.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.